<DOC>
	<DOC>NCT02600468</DOC>
	<brief_summary>The purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of ORENCIA Intravenous Infusion 250mg in patients with rheumatoid arthritis.</brief_summary>
	<brief_title>Survey on Long-Term Use of ORENCIAÂ® Intravenous Infusion 250mg</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients who are beginning to receive the treatment with ORENCIA Intravenous Infusion 250mg under the approved indications, dosage, and administration Have available HAQ data Have available DAS28ESR or DAS28 CRP data Have no past or present history of malignancies Are expected to be followed up for 3 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>